• Suche
1 Aktie gratis
Trading
Suche
1 Aktie gratis
Wertpapierhandel für 0 Euro
Trading
zero-Trading
ETF-Sparplan

Novartis Aktie

79,93EUR
-0,89EUR
-1,10%
28.06.2022
L&S
80,36CHF
-1,19CHF
-1,46%
28.06.2022
BTE

WKN: 904278 / ISIN: CH0012005267

  Kaufen  
Verkaufen
oder
mehr Daten anzeigen
Werbung

Novartis Aktien News

24.06.22Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia (GlobeNewswire)
23.06.22Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments (GlobeNewswire)
23.06.22Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors (GlobeNewswire)
Novartis-Aktie für 0 Euro handeln bei finanzen.net zero
(Werbung)
21.06.22Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent (GlobeNewswire)
17.06.22Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA (GlobeNewswire)
16.06.22New research reveals the critical actions needed to ensure COVID-19-driven surge in virtual health and care drives health access and equity (GlobeNewswire)
12.06.22Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL (GlobeNewswire)
12.06.22Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL (GlobeNewswire)
09.06.22SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS (PR Newswire)
07.06.22Novartis Scemblix®, with novel mechanism of action, shows superior, long-term efficacy and consistent tolerability in 96-week follow-up of chronic myeloid leukemia trial (GlobeNewswire)
06.06.22Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study (GlobeNewswire)
31.05.22Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030 (GlobeNewswire)
28.05.22FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma (GlobeNewswire)
27.05.22Sandoz appoints new Board representative to global AMR Industry Alliance (GlobeNewswire)
20.05.22Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions (GlobeNewswire)
12.05.22Novartis data at ASCO and EHA showcase latest oncology research and innovation, including in breast and prostate cancer (GlobeNewswire)
04.05.22New Novartis data demonstrate only Kisqali® offers more life in the first-line setting for postmenopausal HR+/HER2- advanced breast cancer patients (GlobeNewswire)
27.04.22Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study (GlobeNewswire)
26.04.22Novartis delivers solid sales and profit growth. Strong performance of in-market brands supports confidence in mid-term growth outlook (GlobeNewswire)
26.04.22Novartis erzielt ein solides Umsatz- und Gewinnwachstum. Die starke Performance auf dem Markt befindlicher Marken stützt das Vertrauen in die mittelfristigen Wachstumsaussichten (GlobeNewswire)
22.04.22Novartis receives positive CHMP opinion for Tabrecta® for patients with METex14 advanced non-small cell lung cancer (GlobeNewswire)
14.04.22Sandoz launches generic brimonidine tartrate/timolol maleate eyedrop in US for patients with ocular hypertension, expanding leading ophthalmic portfolio (GlobeNewswire)
06.04.22Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR) (GlobeNewswire)
06.04.22FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS) (GlobeNewswire)
05.04.22Novartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility (GlobeNewswire)
04.04.22Novartis announces new organizational structure to accelerate growth, strengthen pipeline and increase productivity (GlobeNewswire)
04.04.22Novartis gibt neue Organisationsstruktur bekannt für schnelleres Wachstum, eine stärkere Pipeline und höhrere Produktivität (GlobeNewswire)
25.03.22Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease (GlobeNewswire)
25.03.22Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe (GlobeNewswire)
23.03.22Novartis PluvictoTM approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer (GlobeNewswire)
14.03.22Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce (GlobeNewswire)
14.03.22Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection (GlobeNewswire)
04.03.22Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
04.03.22Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut (GlobeNewswire)
18.02.22Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine (GlobeNewswire)
02.02.22Novartis steigert die Dividende das 25. Jahr in Folge (MyDividends)
02.02.22Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021 (GlobeNewswire)
02.02.22Novartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voran (GlobeNewswire)
10.01.22Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19 (GlobeNewswire)
04.01.22Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent (GlobeNewswire)
Seite: 1234567

Novartis News

Novartis News: auf dieser Seite finden Sie alle Novartis News und Nachrichten zur Novartis Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novartis News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novartis News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.

Newssuche

GO
Werbung

Meistgelesene Novartis News

17.06.22Mereo-Aktie +62%: AstraZeneca prüft offenbar Übernahme von Mereo BioPharma - AstraZeneca-Aktie profitiert
31.05.22Experten sehen bei Novartis-Aktie Potenzial
30.05.22Novartis-Aktie nahezu unverändert: Novartis erhält dritte FDA-Zulassung für Krebsmedikament Kymriah
22.06.22Novartis-Aktie verbilligt sich: Novartis will Patent für Gilenya-Dosierungsschema 'energisch' verteidigen
23.06.22Novartis investiert 150 Millionen Dollar in Malaria-Forschung
22.06.22Novartis verliert Rechtsstreit zu Gilenya-Patent in USA
24.06.22Press Release: Novartis receives positive CHMP opinion for Scemblix(R), a novel treatment for adult patients with chronic myeloid leukemia
06.06.22Press Release: Novartis Tafinlar(R) (dabrafenib) + Mekinist(R) (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grad...
06.06.22Press Release: Novartis Tafinlar(R) (dabrafenib) -2-
21.06.22Press Release: Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya(R) (fingolim...
Weitere Novartis News

Novartis Peer Group News

28.06.22Aktien Schweiz nach jüngsten Gewinnen etwas schwächer
28.06.22Sanofi-Aktie dennoch in Rot: EU erteilt Zulassung für Xenpozyme
28.06.22AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer
28.06.22Sanofi (SNY) Wins Nod for Nexviadyme & Xenpozyme in Europe
28.06.22Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
28.06.22Roivant, Pfizer unveil Priovant Therapeutics focused on autoimmune disease treatments, Roivant stock surges
28.06.22Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus
28.06.22Marktüberblick: Pharma & HealthCare gesucht
28.06.22Marktüberblick: Pharma & HealthCare gesucht
28.06.22Marktüberblick: Pharma & HealthCare gesucht
finanzen.net zero

Aktien kaufen ohne Gebühren

finanzen.net zero
Aktien, ETFs, Derivate, Kryptos und mehr jetzt für 0 Euro pro Trade handeln!
JETZT INFORMIEREN
Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
JETZT MEHR ERFAHREN
Zur klassischen Ansicht wechseln
Hilfe & Kontakt
Impressum
Werben
Presse
mehr anzeigen